Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma

Journal of B.U.ON.

Volumn 19, Issue 4, 2014, Pages 1111-1120

  Jakovljevic, Mihajlo ^a   Gutzwiller, Florian ^b   Schwenkglenks, Matthias ^b   Milovanovic, Olivera ^a   Rancic, Nemanja ^c   Varjacic, Mirjana ^d   Stojadinovic, Dobrivoje ^d   Dagovic, Aleksandar ^e   Matter Walstra, Klazien ^b  

^a University of Kragujevac Medical Faculty   (Serbia)

^b Institut für Pharmazeutische Medizin ECPM   (Switzerland)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d University Clinical Center Kragujevac   (Serbia)

^e CLINICAL CENTER KRAGUJEVAC   (Serbia)

Author keywords

Cancer; Costs; Monoclonal antibodies; Resource use; Serbia

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PREDNISOLONE; RITUXIMAB; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ABSENTEEISM; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; COLORECTAL CARCINOMA; COST OF ILLNESS; DRUG COST; EMPLOYMENT STATUS; FEMALE; HEALTH CARE UTILIZATION; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SERBIA; BREAST TUMOR; COLORECTAL TUMOR; ECONOMICS;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG COSTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; RETROSPECTIVE STUDIES;

EID: 84918788258     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003;54:343-369.
2. Simoens S. Health economics of market access for biopharmaceuticals and biosimilars. J Med Econ 2009;12:211-218.
3. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21:89-103.
4. Center for Medicare & Medicaid Services. Updated and extended national health expenditure projections, 2010-2019. Washington, DC: US Department of Health & Human Services, 2011.
5. Ogura S. Revisiting the Japanese comprehensive reimbursement scheme for the elderly outpatients during 1996-2002 period: How it affected Japanese healthcare practices. Japan J Health Economics Policy 2010;21:191-212.
6. Wild F. Increases in pharmaceutical expenditures of PHI by monoclonal antibodies. Versicherungsmedizin 2013;65:91-93.
7. Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 2008;8:523-532.
8. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-319.
9. Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars 2011;1:1-11.
10. Akiyama S. Specific adverse events caused by monoclonal antibodies, focusing on the prophylaxis and management. Nihon Rinsho 2012;70:2199-2204.
11. Puder KL, Wood LL, Sherrill A. Health economics with retrospective data: selection bias issues. J Int Med Res 1997;25:45-51.
12. Shih YC, Elting LS, Pavluck AL, Stewart A, Halpern MT Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin, s Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer. Cancer Investig 2010;28:46-53.
13. Jakovljevic M, Jovanovic M, Lazic Z et al. Current efforts and proposals to reduce healthcare costs in Serbia. Serb J Exp Clin Res 2011;12:161-163.
14. Milijus D, Zivkovic S, Bozic Z (Eds): Cancer incidence and mortality in central Serbia. Report No. XII. Beograd: Institute of Public Health of Serbia "Dr Milan Jovanovic Batut", 2012.
15. El Saghir NS, Eniu A, Carlson RW et al. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer 2008;113(8 Suppl):2315-2324.
16. Vogl TJ, Schmiegel W, Pox C et al. S3 guideline-Diagnosis and treatment of colorectal carcinoma: relevance for radiologic imaging and interventions. Rofo 2013;185:699-708.
17. Faber LM, Van Agthoven M, Uyl-De Groot CA, Lowenberg B, Huijgens PC. Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: variation in guidelines and in practice. Ned Tijdschr Geneeskd 2000;144:1223-1227.
18. Zweifel P. The Grossman model after 40 years. Eur J Health Econ 2012;13:677-682.
19. Zhao Z, Pelletier E, Barber B et al. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Curr Med Res Opin 2012;28:221-229.
20. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009;23:289-304.
21. Fornier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 2000;27(6 Suppl 11):58-45; discussion 92-100.
22. Tilly H, Vitolo U, Walewski J et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012(Suppl 7): vii78-82.
23. Lopez-Guillermo A, Caballero D, Canales M et al. Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. Leuk Lymphoma 2011;52(Suppl 3):1-14.
24. Gershanovich ML, Tikhonova W. Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy. Vopr Onkol 2004;50:602-604.
25. Aapro MS. Biosimilars in oncology: current and future perspectives, Generics and Biosimilars Initiative Journal (GaBI Journal) 2012;2(2): Epub ahead of print. DOI: 10.5639/gabij.2013.0202.023
26. Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011;17:6338-6346.
27. Johnsen HE, Haioun C, Lugtenburg PJ et al. Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma 2012;53:982-984.
28. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008;77:311-319.
29. Fratino L, Crivellari D, Spina M et al. Use of biological drugs in elderly cancer patients: A sustainable reality? A mono-institutional experience. Int J Clin Oncol 2007;2518(Suppl):19665 (meet abstr).
30. Murata C, Yamada T, Chen CC, Ojima T, Hirai H, Kondo K. Barriers to health care among the elderly in Japan. Int J Environ Res Public Health 2010;7:1330-1341.
31. Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. MAbs 2009;1:56-66.
32. Epstein RJ, Cheung BM. Loading doses for costly cancer biologicals: sound pharmacology or unnecessary extravagance? Eur J Cancer 2008;44:1488-1492.
33. Tigue CC, Fitzner KA, Alkhatib M, Schmid E, Bennett CL. The value of innovation: the economics of targeted drugs for cancer. Target Oncol 2007;2:113-119.
34. Tirelli U, Berretta M, Bearz A, Carbone A. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis. Eur Rev Med Pharmacol Sci 2011;15:1355-1356.
35. Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care 2005;21:132-137.
36. Brodszky V, Orlewska E, Pentek M, Karpati K, Skoupa J, Gulacsi L. Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. Med Sci Monit 2010;16:SR1-5.
37. Kos M, Obradovic M, Mrhar A. Accessibility to targeted oncology drugs in Slovenia and selected European countries. Eur J Cancer 2008;44:408-418.
38. Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health 2010;13:837-845.
39. Leonard CE, Freeman CP, MacCurdy T et al. Utilization and cost of anticancer biologic products among Medicare beneficiaries, 2006-2009: Data Points #6. In: Data Points Publication Series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. http://www.ncbi.nlm.nih.gov/books/NBK65148
40. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013;14:153-159.
41. Ilic MS. Pharmacoeconomic analysis of antineoplastics at the Oncology Institute of Vojvodina from 2005 to 2008. Archive Oncol 2009;17:78-79.
42. Winger BJ, Clements EA, De Young JL et al. Cost savings from dose rounding of biologic anticancer agents in adults. J Oncol Pharm Pract 2011;17:246-251.
43. Jakovljevic M, Rankovic A, Racic N et al. Radiology Services Costs and Utilization Patterns estimates in Southeastern Europe - A Retrospective Analysis from Serbia. Value Health Regional Issues 2013;2:218-225.
44. Rankovic A, Rancic N, Jovanovic M et al. Impact of imaging diagnostics on the budget-are we spending too much? Vojnosanit Pregl 2013;70:709-711.
45. Gulacsi L. Future challenges for health economics and health technology assessment of biological drugs. Eur J Health Econ 2010;11:235-238.
46. Motheral B, Brooks J, Clark MA et al. A checklist for retrospective database studies-report of the ISPOR Task Force on Retrospective Databases. Value Health 2003;6:90-97.
47. Haley ML, Gerszten PC, Heron DE, Chang YF, Atteberry DS, Burton SA. Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J Neurosurg Spine 2011;14:537-542.
48. Radovanovic A, Dagovic A, Jakovljevic M. Economics of cancer related medical care: Worldwide estimates and available domestic evidence. Archive Oncol 2011;19:59-63.
49. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009;6:550-552.
50. Knezevic I, Griffiths E. Biosimilars-global issues, national solutions. Biologicals 2011;39:252-255.
51. Konski AF. Generic Biologics - A Comparative Analysis of Regulatory Review. BioProcess Intern 2011;9:34-39.
52. Roger SD, Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther 2008;33:459-464.
53. Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848:8-18.
54. Scolnik PA. MAbs: a business perspective. MAbs 2009;1:179-184.
55. Ziegelbauer K, Light DR. Monoclonal antibody therapeutics: Leading companies to maximise sales and market share. J Commercial Biotechnol 2007;14:65-72.
56. Uyl-De Groot CA, De Groot S, Steenhoek A. The economics of improved cancer survival rates: better outcomes, higher costs. Expert Rev Pharmacoecon Outcomes Res 2010;10:283-292.
57. Yamada T, Chia-Ching C, Tadashi Y, I-Ming C, John D. Worrall Pharmaceutical Price Control Policy, Pharmaceutical Innovation, and Health Durability. Open Pharmacoecon Health Econ J 2010;2:34-46.
58. Jakovljevic MB. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia. Health economics and therapeutic pathways 2014;15:27-32.